Essential medicines for pediatric oncology in developing countries

Página do item simplificado
dc.contributor.authorMehta, Parth S.
dc.contributor.authorWiernikowski, John T.
dc.contributor.authorSergio Petrilli, J. A. [UNIFESP]
dc.contributor.authorBarr, Ronald D.
dc.contributor.authorSIOP
dc.contributor.institutionBaylor Coll Med
dc.contributor.institutionMcMaster Childrens Hosp
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionMcMaster Univ
dc.date.accessioned2016-01-24T14:31:39Z
dc.date.available2016-01-24T14:31:39Z
dc.date.issued2013-05-01
dc.description.abstractThe burden of cancer in children in low and middle income countries (LMICs) is substantial, comprising at least 80% of incident cases globally, and an even higher proportion of cancer-related deaths. With survival rates exceeding 80% in high income countries, it is imperative to transfer these successes to LMICs. A major challenge is the poor availability of safe, cost-effective chemotherapy. A list of 51 drugschemotherapeutics, infectious disease agents, and supportive care medicationsis proposed as essential to improving the survival of children with cancer in LMICs with an additional 13 drugs identified as being of further value. Pediatr Blood Cancer 2013; 60: 889891. (c) 2013 Wiley Periodicals, Inc.en
dc.description.affiliationBaylor Coll Med, Dept Pediat, Hematol Oncol Sect, Houston, TX 77030 USA
dc.description.affiliationBaylor Coll Med, Dept Pediat, Hematol Oncol Sect, Gaborone, Botswana
dc.description.affiliationMcMaster Childrens Hosp, Hamilton, ON, Canada
dc.description.affiliationUniversidade Federal de São Paulo, Sch Med, Pediat Oncol Inst, São Paulo, Brazil
dc.description.affiliationMcMaster Univ, Dept Pediat, Hamilton, ON, Canada
dc.description.affiliationMcMaster Univ, Dept Pathol, Hamilton, ON, Canada
dc.description.affiliationMcMaster Univ, Dept Med, Hamilton, ON, Canada
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Sch Med, Pediat Oncol Inst, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent889-891
dc.identifierhttp://dx.doi.org/10.1002/pbc.24476
dc.identifier.citationPediatric Blood & Cancer. Hoboken: Wiley-Blackwell, v. 60, n. 5, p. 889-891, 2013.
dc.identifier.doi10.1002/pbc.24476
dc.identifier.issn1545-5009
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/36268
dc.identifier.wosWOS:000316291700031
dc.language.isoeng
dc.publisherWiley-Blackwell
dc.relation.ispartofPediatric Blood & Cancer
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.rights.licensehttp://olabout.wiley.com/WileyCDA/Section/id-406071.html
dc.subjectchemotherapyen
dc.subjectHIVen
dc.subjectpediatric oncologyen
dc.subjectsarcomaen
dc.subjectsupport careen
dc.subjectquality of lifeen
dc.titleEssential medicines for pediatric oncology in developing countriesen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
EPM - Artigos